1. Home
  2. OMER vs PCB Comparison

OMER vs PCB Comparison

Compare OMER & PCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • PCB
  • Stock Information
  • Founded
  • OMER 1994
  • PCB 2003
  • Country
  • OMER United States
  • PCB United States
  • Employees
  • OMER N/A
  • PCB N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • PCB Major Banks
  • Sector
  • OMER Health Care
  • PCB Finance
  • Exchange
  • OMER Nasdaq
  • PCB Nasdaq
  • Market Cap
  • OMER 274.3M
  • PCB 315.4M
  • IPO Year
  • OMER 2009
  • PCB N/A
  • Fundamental
  • Price
  • OMER $4.48
  • PCB $20.56
  • Analyst Decision
  • OMER Strong Buy
  • PCB Hold
  • Analyst Count
  • OMER 5
  • PCB 2
  • Target Price
  • OMER $18.00
  • PCB $22.25
  • AVG Volume (30 Days)
  • OMER 933.6K
  • PCB 23.7K
  • Earning Date
  • OMER 11-12-2025
  • PCB 10-23-2025
  • Dividend Yield
  • OMER N/A
  • PCB 3.90%
  • EPS Growth
  • OMER N/A
  • PCB 29.75
  • EPS
  • OMER N/A
  • PCB 2.14
  • Revenue
  • OMER N/A
  • PCB $102,259,000.00
  • Revenue This Year
  • OMER N/A
  • PCB $22.59
  • Revenue Next Year
  • OMER N/A
  • PCB $9.32
  • P/E Ratio
  • OMER N/A
  • PCB $9.59
  • Revenue Growth
  • OMER N/A
  • PCB 9.08
  • 52 Week Low
  • OMER $2.95
  • PCB $16.00
  • 52 Week High
  • OMER $13.60
  • PCB $22.45
  • Technical
  • Relative Strength Index (RSI)
  • OMER 56.41
  • PCB 40.01
  • Support Level
  • OMER $4.07
  • PCB $20.53
  • Resistance Level
  • OMER $4.72
  • PCB $21.00
  • Average True Range (ATR)
  • OMER 0.23
  • PCB 0.40
  • MACD
  • OMER 0.02
  • PCB -0.08
  • Stochastic Oscillator
  • OMER 61.19
  • PCB 4.43

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About PCB PCB Bancorp

PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.

Share on Social Networks: